Skip to main content

Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients

Osteoporosis International volume 31, pages 973–980 (2020)Cite this article

A Correction to this article was published on 18 March 2020

This article has been updated

Abstract

Summary

A retrospective chart review was conducted on 85 renal transplant patients aged 19–88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; at years 1, 2, and 3; and at final follow-up (average of 3.4 years).

Both bisphosphonate and denosumab treatments increased lumbar spine bone density; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Denosumab treatment increased femoral neck BMD, whereas bisphosphonate treatment had a mean decrease in femoral neck BMD at final follow-up. Thus, our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant.

Introduction

To compare the clinical effectiveness and safety between the use of denosumab and bisphosphonates on bone density and incidence of adverse events in renal transplant patients.

Methods

A retrospective chart review was conducted on 85 renal transplant patients aged 19–88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; years 1, 2, and 3; and at final follow-up (average of 3.4 years).

Results

Absolute change in lumbar spine and femoral neck BMD over the treatment period was 0.029 ± 0.075 g/cm2 and − 0.003 ± 0.064 g/cm2, respectively, in the bisphosphonate group. Absolute change in lumbar spine and femoral neck BMD at final follow-up was 0.072 ± 0.094 g/cm2 and 0.025 ± 0.063 g/cm2, respectively, in the denosumab group. Denosumab resulted in significantly greater increases in lumbar spine BMD (0.045 g/cm2 greater in the denosumab group). Similarly, the absolute change in BMD at the femoral neck was 0.022 g/cm2 greater in the denosumab group as compared with the bisphosphonate group. The denosumab group had one event of severe hypocalcemia following first injection and one report of hospitalized pneumonia. No serious adverse events were reported in the bisphosphonate group.

Conclusions

Both treatments increased lumbar spine BMD; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

Change history

  • 18 March 2020

    The original version of this article, published on 03 January 2020 contained a mistake. An author’s name was misspelled.

References

  1. Nitta K, Yajima A, Tsuchiya K (2017) Management of osteoporosis in chronic kidney disease. Intern Med 56:3271–3276

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Malluche HH, Monier-Faugere M-C, Herberth J (2009) Bone disease after renal transplantation. Nat Rev Nephrol 6:32

    PubMed  PubMed Central  Google Scholar 

  3. Brandenburg VM, DPMKWJFNHRWTFJFTHI (2004) Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 77:1566–1571

    PubMed  PubMed Central  Google Scholar 

  4. Monier-Faugere M-C, Mawad H, Qi Q, Friedler RM, Malluche HH (2000) High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11:1093 LP–1091099

    Google Scholar 

  5. Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N (2009) Risk of fractures after renal transplantation in the United States. Transplantation 87:1846–1851

    PubMed  PubMed Central  Google Scholar 

  6. Sukumaran Nair S, Lenihan CR, Montez-Rath ME, Lowenberg DW, Chertow GM, Winkelmayer WC (2014) Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States. Am J Transplant 14:943–951

    PubMed  PubMed Central  Google Scholar 

  7. Cruz EAS, Lugon JR, Jorgetti V, Draibe SA, Carvalho AB (2004) Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis 44:747–756

    PubMed  PubMed Central  Google Scholar 

  8. Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731

    PubMed  PubMed Central  Google Scholar 

  9. Bianchi ML, Colantonio G, Montesano A, Trevisan C, Ortolani S, Rossi R et al (1992) Bone mass status in different degrees of chronic renal failure. Bone 13:225–228

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, McMahon D, Liu XS, Boutroy S, Cremers S, Shane E (2013) Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28:1811–1820

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Chapter 1: Introduction and definition of CKD–MBD and the development of the guideline statements. Kidney Int 2009; 76: S3–S8

  12. Hill Gallant KM, Spiegel DM (2017) Calcium balance in chronic kidney disease. Curr Osteoporos Rep 15:214–221

    PubMed  PubMed Central  Google Scholar 

  13. Jamal SA, West SL, Miller PD (2012) Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep 14:217–223

    CAS  PubMed  PubMed Central  Google Scholar 

  14. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197

    PubMed  PubMed Central  Google Scholar 

  15. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Augoulea A, Tsakonas E, Triantafyllopoulos I, Rizos D, Armeni E, Tsoltos N et al (2017) Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. 17:444–449

  17. Miller PD (2011) The kidney and bisphosphonates. Bone 49:77–81

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13:962–969

    PubMed  PubMed Central  Google Scholar 

  19. Bover J, Bailone L, López-Báez V, Benito S, Ciceri P, Galassi A, Cozzolino M (2017) Osteoporosis, bone mineral density and CKD–MBD: treatment considerations. J Nephrol 30:677–687

    PubMed  PubMed Central  Google Scholar 

  20. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96:1727–1736

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886–1894

    PubMed  PubMed Central  Google Scholar 

  24. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial*. J Bone Miner Res 24:153–161

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Beaudoin C, Jean S, Bessette L, Ste-Marie L-G, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27:2835–2844

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163–3170

    CAS  PubMed  PubMed Central  Google Scholar 

  27. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832–1841

    CAS  PubMed  PubMed Central  Google Scholar 

  29. McCormick BB, Davis J, Burns KD (2012) Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 60:626–628

    PubMed  PubMed Central  Google Scholar 

  30. Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Suzuki H, Kihara M, Mano S, Kobayashi T, Kanaguchi Y, Hidaka T et al. Efficacy and safety of denosumab for the treatment of osteoporosis in patients with chronic kidney disease. J Clin Exp Nephrol 2017; 02. doi:https://doi.org/10.21767/2472-5056.100030

  32. Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, Sharma K, Wijarnpreecha K, Ungprasert P, Gonzalez Suarez ML, Cheungpasitporn W (2018) Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients : a meta-analysis of observational studies. Osteoporos Int 29:1737–1745

    CAS  PubMed  PubMed Central  Google Scholar 

  33. McClung MR (2017) Denosumab for the treatment of osteoporosis. Osteoporos Sarcopenia 3:8–17

    PubMed  PubMed Central  Google Scholar 

  34. Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677–692

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Do W-S, Park J-K, Park M-I, Kim H-S, Kim S-H, Lee D-H (2012) Bisphosphonate-induced severe hypocalcemia-a case report. J Bone Metab 19:139–145

    PubMed  PubMed Central  Google Scholar 

  36. Pittman K, Antill YC, Goldrick A, Goh J, de Boer RH (2017) Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac J Clin Oncol 13:266–276

    PubMed  PubMed Central  Google Scholar 

  37. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22:503–508

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105–2115

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 60:324–333

    PubMed  PubMed Central  Google Scholar 

  40. Saleh A, Hegde VV, Potty AG, Lane JM (2013) Bisphosphonate therapy and atypical fractures. Orthop Clin North Am 44:137–151

    PubMed  PubMed Central  Google Scholar 

  41. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13–20

    CAS  PubMed  PubMed Central  Google Scholar 

  42. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021

    PubMed  PubMed Central  Google Scholar 

  43. Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044–1052

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

  1. McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada

    H. McKee, G. Ioannidis, A. Lau, D. Treleaven, A. Gangji, C. Ribic, M. Wong-Pack, A. Papaioannou & J. D. Adachi

Authors
  1. H. McKee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Ioannidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Treleaven
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Gangji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Ribic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Wong-Pack
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Papaioannou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. D. Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. McKee.

Ethics declarations

Conflicts of interest

None.

Ethical approval

This study was approved by the Hamilton Integrated Research Ethics Board number 5091-C.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: An author’s name was misspelled.

Appendix

Appendix

Fig. 2
figure 2

Inclusion and exclusion criteria

Full size image

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McKee, H., Ioannidis, G., Lau, A. et al. Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients. Osteoporos Int 31, 973–980 (2020). https://doi.org/10.1007/s00198-019-05267-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-019-05267-1

Keywords

  • Bisphosphonates
  • CKD
  • Denosumab
  • Osteoporosis
  • Renal transplant